Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.

被引：11
|
作者：
Higano, Celestia S.
Sternberg, Cora N.
Saad, Fred
Tombal, Bertrand F.
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Sartor, A. Oliver
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA
[4] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[5] Clin Univ St Luc, Brussels, Belgium
[6] Charite, Dept Urol, Berlin, Germany
[7] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland
[8] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[9] Tulane Med Sch, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
256
引用
收藏
页数：1
相关论文
共 50 条
  • [31] REAL-WORLD TREATMENT PATTERNS AND TREATMENT SEQUENCES IN THE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER SETTINGS ACROSS EUROPE
    Castro, E.
    Orji, C.
    Ribbands, A.
    Butcher, J.
    Walley, M.
    Li, W.
    Ghate, S.
    VALUE IN HEALTH, 2024, 27 (06) : S227 - S227
  • [32] Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
    Liu, Min
    Yan, Jiaqing
    Le, Kaidi
    Li, Ying
    Xing, Nianzeng
    Li, Guohui
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [33] Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
    Morgans, A. K.
    Divan, H. A.
    Birtle, A. J.
    Dorff, T.
    Ozatilgan, A.
    Graff, J. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 334 - 334
  • [34] Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide
    Scailteux, Lucie-Marie
    Vincendeau, Sebastien
    Gravis, Gwenaelle
    Mathieu, Romain
    Balusson, Frederic
    Kerbrat, Sandrine
    Oger, Emmanuel
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : E362 - E369
  • [35] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [36] Real world treatment utilization patterns in patients with castration-resistant prostate cancer
    Vigneswaran, Hari T.
    Warnqvist, Anna
    Andersson, Therese M. L.
    Leval, Amy
    Eklund, Martin
    Nordstrom, Tobias
    Eloranta, Sandra
    Schain, Frida
    Dearden, Lindsay
    Liwing, Johan
    Mehra, Maneesha
    Nair, Sandhya
    Pettersson, Andreas
    Akre, Olof
    Aly, Markus
    SCANDINAVIAN JOURNAL OF UROLOGY, 2021, 55 (04) : 299 - 306
  • [37] Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations
    Stewart, T. F.
    Gedrich, R.
    Saha, J.
    Chirnomas, D.
    Edwards, M.
    Lang, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1188 - S1188
  • [38] Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    George, Daniel J.
    Sternberg, Cora N.
    Sartor, A. Oliver
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [39] Real world outcomes with cabazitaxel (cab) plus carboplatin (car) in metastatic castration-resistant prostate cancer (mCRPC)
    Vemuru, Shalini
    Goyal, Subir
    Liu, Yuan
    Zhuang, Tony
    Patel, Deven
    Kucuk, Omer
    Carthon, Bradley Curtis
    Nazha, Bassel
    Bilen, Mehmet Asim
    Brown, Jacqueline T.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Prevalence of castration-resistant prostate cancer (CRPC) of unknown metastatic status in the real-world setting: The AfrODiTA study
    Rodrigo-Aliaga, M.
    Alvarez-Ossorio, J. L.
    Rodriguez-Alonso, A.
    Garcia Garcia-Porrero, A.
    Quesada-Garcia, A.
    Munoz del Toro, J.
    Rodriguez-Antolin, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S646 - S646
12345